AARTIDRUGS vs GRANULES: Stock Comparison

AARTI DRUGS vs GRANULES INDIAUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

GRANULES INDIA is the larger company by market capitalisation. AARTI DRUGS shows a lower P/E, a higher ROE and a higher dividend yield, while GRANULES INDIA shows faster revenue growth, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 7; GRANULES leads 6 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSGRANULES

Valuation lens

What price are you paying?

Market CapContext only
₹3,973 Cr
₹21,073 Cr
P/E RatioAARTIDRUGS has the lower reading
20x
31.03x
P/B RatioAARTIDRUGS has the lower reading
2.47x
4.08x
EPSAARTIDRUGS has the higher reading
₹5.57
₹2.9
Book ValueContext only
₹169.74
₹205.21
Dividend YieldAARTIDRUGS has the higher reading
0.46%
0.21%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GRANULES is the larger company
₹21,073 Cr vs ₹3,973 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
20x vs 31.03x
P/B Ratio
AARTIDRUGS has a lower P/B
2.47x vs 4.08x
EPS
AARTIDRUGS has higher earnings per share
₹5.57 vs ₹2.9
Dividend Yield
AARTIDRUGS has a higher dividend yield
0.46% vs 0.21%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 6.4%
EPS Growth (TTM YoY)
GRANULES has faster EPS growth
31.3% vs -12%
Qtr Sales Growth
AARTIDRUGS has stronger quarterly sales growth
-10.72% vs -45.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSGRANULES
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSGRANULES
Live Price₹431.65₹848.3
Day Change1.36%-0.65%
Volume2.5 L11.73 L
52-Week High₹534.55₹910
52-Week Low₹318.95₹507.3
Distance from 52W High-19.25%-6.78%

Valuation

MetricAARTIDRUGSGRANULES
Market Cap₹3,973 Cr₹21,073 Cr
P/E Ratio20x31.03x
P/B Ratio2.47x4.08x
EPS₹5.57₹2.9
Book Value₹169.74₹205.21
Dividend Yield0.46%0.21%

Growth

MetricAARTIDRUGSGRANULES
Revenue Growth (TTM YoY)6.4%22.8%
EPS Growth (TTM YoY)-12%31.3%
Qtr Sales Growth-10.72%-45.7%
Qtr Profit Growth1.44%-60.13%

Profitability & Leverage

MetricAARTIDRUGSGRANULES
ROE12.05%11.7%
ROCE10.64%12.47%
Net Margin7.6%11.15%
Operating Margin9.19%16.76%
Debt to Equity0.3x0.26x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIDRUGSGRANULES
Promoter Holding54.43% 0.6 pp37.67%
FII Holding1.52% 0.06 pp17.5% 2.19 pp
DII Holding10.29% 0.07 pp16.11% 0.9 pp
Public Holding33.75% 0.57 pp28.38% 1.28 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and GRANULES INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.